Ultra Market Research | Active Pharmaceutical Ingredient Market
Active Pharmaceutical Ingredient Market
Report ID : 600
Category : Pharmaceuticals
No Of Pages : 150
Published on: July 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Active Pharmaceutical Ingredient Market Market for active pharmaceutical ingredients was estimated to be worth US$ XX billion globally in 2023 and is projected to increase at a compound annual growth rate (CAGR) of XX% from 2024 to 2033, reaching around US$ XX billion. In several medical specialities, such as cardiology, cancer, neurology, pulmonology, gastroenterology, nephrology, ophthalmology, and endocrinology, the integration of Active Pharmaceutical Ingredients (APIs) is essential to growth. The foundation of premium medications are active pharmaceutical ingredients (APIs), which impact physiological processes and provide the pharmacological activity necessary for illness diagnosis, treatment, and prevention. Through the use of APIs, the healthcare industry may promote innovation and increase the sustainability of healthcare systems by creating more sophisticated and potent therapeutic treatments.
Market Overview Market for active pharmaceutical ingredients (APIs) is expanding quickly because of its essential function as the main component of drugs that is in charge of producing the intended therapeutic effects. Biologically active ingredients (APIs) are found in a variety of pharmaceutical forms, including tablets, capsules, creams, and injectables. They are sometimes referred to as drug substances or pharmacologic substances. They influence physiological processes and treat illnesses through their pharmacological actions. Active ingredient prescribing appears as an approach to reduce medication errors because certain drugs contain multiple APIs that work in different ways within the body. The fact that many medications with different brand names have the same active components highlights the importance of APIs in pharmaceutical formulations and their potential for industry standardisation.
Key Insights
• North America region hit a largest market share. • Asia Pacific region is growing at the highest CAGR. • By type of manufacturer, the captive API segment has garnered the highest market share. • By type, the innovative APIs segment accounted largest market share. • By application, the cardiovascular diseases segment exhibited a largest market share. However, the oncology segment is growing at CAGR over the forecast period. • By type of synthesis, the synthetic API segment accounted largest market share. However, the biotech segment is growing at largest CAGR over the forecast period.
Regional Stance North America is the leading region in the world market for active pharmaceutical ingredients (APIs), but it has difficulties because more than 80% of critical medications and important therapeutic APIs are not manufactured in the US. Only 5 percent of significant API sites are located in the United States; most are hosted in China and India. This discrepancy is a result of international pricing forces that favour non-US producers who receive government subsidies, lower input costs, and laxer regulations. In order to protect the security of US healthcare, the country's manufacturing infrastructure must be strengthened, fair international competition must be promoted, and sustainable home markets must be developed. Policymakers and the media are urged to closely examine the medical supply chain because there is still a significant reliance on foreign factories for APIs, even though US sources primarily involve prohibited chemicals or speciality APIs appropriate for smaller-scale production. Despite these obstacles, biopharmaceutical businesses have strengthened worldwide supply chains; in the last five years, the US has seen a remarkable 50% growth in the number of pharmaceutical production facilities, including those that produce APIs.
With a CAGR expected to surpass other areas, the active pharmaceutical ingredient (API) market in the Asia Pacific area is expected to rise at a quick rate during the forecast period. But there are issues with outsourcing API production to Asia, which could exacerbate supply chain disruptions in the pharmaceutical industry. The pricing pressure that Chinese and Indian manufacturers are applying to their Western counterparts because to their competitiveness in the global market has caused a major shift in the production of pharmaceuticals towards Asia. Asian manufacturers either dominate the market for newer APIs or experience a faster migration rate. The balance of production for most APIs is skewed towards Asia, despite Europe and Asia emerging as the two main centres, highlighting the region's critical significance in the pharmaceutical industry.
Report Highlights By Technology Ease of availability to raw materials and the streamlined synthesis procedures have led to the synthetic segment's rise to prominence in the worldwide active pharmaceutical ingredient (API) market. Chemically synthesised chemicals are created via a variety of chemical reactions; aspirin, paracetamol, and many antibiotics are examples of these molecules. Focused on chemically synthesised APIs and intermediates and pharmaceutical fine chemicals, synthetic APIs dominate the market, demonstrating improvements in technology and manufacturing techniques in the pharmaceutical sector.
By Type There are two main categories of APIs on the market: general and innovative. Globally, new APIs lead the way because of strong legal frameworks, well-established R&D facilities, and increased government funding that support the creation of novel pharmaceuticals. This category is led by innovator medications with particular active components that have received initial approval for usage. These medications are put through rigorous testing to guarantee their quality, safety, and efficacy. The original manufacturer also obtains drug patents for these medications, protecting their market exclusivity for a maximum of 20 years. The original business is granted exclusive rights to manufacture and distribute the drug until the patent expires, providing protection against competition and paving the way for long-term market domination and profitability. Generic APIs are the chemical components that were previously patent-protected in different types of API markets. The active chemicals in these generic medications are the same as those in their innovative equivalents, resulting in the same pharmacological effects. The active component of a generic medication is what gives it its primary therapeutic efficacy. When patents expire, several businesses are able to manufacture these generic drugs, which increases competition and expands the pool of accessible, reasonably priced drugs. This ever-changing landscape of generic APIs highlights their equivalent to innovator medications, facilitating post-patent accessibility and affordability of pharmaceuticals.
By Type of Manufacturers Bulk of revenue in the API industry is earned by captive API producers, whose products are used internally by pharmaceutical firms to create completed dosage forms. In contrast, APIs are sold by third-party sellers in the Merchant API market. Investments in cutting-edge chemical processes for internal API manufacturing are rising as more businesses place a higher priority on cost containment and risk reduction from contamination. The future of API manufacturing will be shaped by developments in artificial intelligence and protein synthesis, which have the potential to further optimise development processes and provide increased control and efficiency. It is anticipated that in the upcoming years, the Merchant APIs market will develop at the fastest rate. This market offers a number of benefits, including the elimination of the need for large capital expenditures for elaborate infrastructure and expensive machinery. Pharmaceutical businesses can therefore improve efficiency and agility in meeting market demands by streamlining their processes and concentrating resources on core skills.
By Application Among the many medical specialities that depend on Active Pharmaceutical Ingredients (APIs) are CNS and neurology, oncology, orthopaedics, cardiology, pulmonology, ophthalmology, gastroenterology, endocrinology, and nephrology. Due to the widespread use of cardiovascular medications in the treatment of ailments including heart failure and vascular problems, the cardiovascular diseases segment leads the API industry. This family of drugs includes angiotensin II receptor antagonists, calcium channel blockers, beta-blockers, lipid modifiers, cardiac glycosides, vasodilators, and vasoconstrictors, among other a variety of cardiovascular chemicals. This highlights the pivotal function of APIs in managing an extensive range of cardiovascular conditions, mirroring the noteworthy portion of the API market occupied by cardiovascular medications. Oncology market is expected to develop at the quickest Compound Annual Growth Rate (CAGR) over the forecast period, making it a significant growth driver in the pharmaceutical industry. In this section, anticancer medications are highlighted as essential parts of Active Pharmaceutical Ingredients (APIs), which are carefully crafted to fight cancer cells. These powerful drugs are essential to the treatment of cancer because they selectively target and destroy cancerous cells, preventing them from proliferating and spreading. Anticancer medications fall into several categories, such as hormone treatment, immunotherapy, targeted therapy, and chemotherapy. Each type of medication is designed to stop the proliferation of malignant cells by a different mode of action.
Market Dynamics Driver Crucial Role of APIs in the Pharmaceutical Industry Essential components of pharmaceutical goods, active pharmaceutical ingredients (APIs) have a significant impact on the therapeutic and clinical efficaciousness of these medicines. Ensuring the safety and efficacy of drugs requires careful consideration of API selection and exact dosing. APIs are the active ingredients that are manufactured or encapsulated in pharmaceutical formulations. Drug formulations use a wide range of ingredients, including excipients, binders, fillers, and coatings, in addition to APIs, to maximise patient adherence, stability, and delivery. The interaction between active pharmaceutical ingredients (APIs) and drug products works in concert to improve patient outcomes and meet medical needs, which in turn drives the growth of the API market.
Restraints Challenges in the Manufacturing of APIs European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) maintain strict regulatory criteria that pose substantial obstacles to the production of Active Pharmaceutical Ingredients (APIs). Adherence to these laws is crucial in guaranteeing the uniformity, security, and effectiveness of active ingredients. Strong quality management systems require significant investments in order to comply with Good Manufacturing Practices (GMP). To successfully maintain regulatory compliance, manufacturers need to carefully record the controls, methods, and validation procedures specified in GMP requirements. Validating manufacturing techniques, keeping thorough records, and conducting regular audits are all crucial components. These strict regulations function as barriers, preventing the market for active medicinal ingredients from expanding.
Opportunities Continuous Processing Innovations for Small-Molecule APIs
Promising potential exist in the pharmaceutical business for small-molecule APIs due to ongoing processing advances. These developments enable photochemical, electrochemical, and serial biochemical catalysis by fusing flow chemistry with unique reaction mechanisms and reactor configurations. Heterogeneous reactions in upstream processes are facilitated by the development of hybrid batch-continuous reactors or intermittent-flow stirred tank reactors, while membrane separations take the role of conventional distillation or crystallisation procedures in downstream processes. It is expected that periodic continuous-chromatography formats would be converted to fully continuous formats, including countercurrent tangential chromatography, in the biologics manufacturing process. Through the management of physical material feedback, these developments present prospects for improved API yield, more economical use of raw materials, decreased waste formation, and improved process control. Opportunities within the active pharmaceutical ingredient are further fuelled by unit operations' acceptance of recirculation.
Recent Developments
• In November 2022, Roquette, a global leader in plant-based ingredients and a prominent provider of pharmaceutical and nutraceutical excipients, launched two next-generation mannitol products for direct compression – PEARLITOL CR-H and PEARLITOL 200 GT • In November 2022, Advent International introduced Cohance Lifesciences, a new brand identity for its API and CDMO platform, consisting of three portfolio companies: RA Chem Pharma, ZCL Chemicals, and Avra Laboratories • In November 2023, EUROAPI completed the acquisition of BianoGMP, enhancing its CDMO expertise in the high-growth oligonucleotide market. • In January 2023, Sterling finalized the acquisition of an API manufacturing facility in Ringaskiddy, Ireland Source: • In April 2024, Evonik bolstered its biosolutions offering with the introduction of a new Botanicals & Natural Actives business segment • In February 2024, Novo Nordisk’s parent company acquired Catalent to enhance the supply of Wegovy Source: https://www.pharmexec.com/view/novo-nordisk-parent-company-catalent-acquisition-wegovy.
Key Players in the Active Pharmaceutical Ingredient Market Albemarle Corporation AurobindoPharma Reddy’s Laboratories Ltd. AbbVieInc Teva Pharmaceutical Industries Ltd Mylan N.V. CiplaInc BoehringerIngelheim International GmbH Merck & Co., Inc Sun Pharmaceutical Industries Ltd Bristol-Myers Squibb Company
Market Segmentation By Type of Synthesis Biotech Monoclonal Antibodies Recombinant Proteins Vaccines Synthetic
By Type of Manufacturer Captive APIs Merchant APIs Generic APIs Innovative APIs
By Geography North America U.S. Canada Europe Germany France United Kingdom Rest of Europe Asia Pacific China Japan India Southeast Asia Rest of Asia Pacific Latin America Brazil Rest of Latin America Middle East & Africa (MEA) GCC North Africa South Africa Rest of Middle East & Africa
Table of content 1. Introduction 1.1. Report Description 1.2. Research Methodology 1.2.1. Data Mining 1.2.2. Market Modeling and Forecasting 1.2.3. Data Validation 1.2.7. Industry Analysis
4. Active Pharmaceutical Ingredient Market by Application 4.1. Introduction 4.2. Active Pharmaceutical Ingredient Market Size and Growth Rate by Application (2021-2030) 4.3. Biotech 4.3.1. Biotech Market Size and Growth Rate (2019- 2030) 4.7. Monoclonal Antibodies 4.7.1. Monoclonal Antibodies Market Size and Growth Rate (2019- 2030) 4.5. Recombinant Proteins 4.5.1. Recombinant Proteins Market Size and Growth Rate (2021-2030) 4.6. Vaccines 4.6.1. Vaccines Market Size and Growth Rate (2021-2030) 4.7. Synthetic 4.7.1. Synthetic Market Size and Growth Rate (2021-2030)
5. Active Pharmaceutical Ingredient Market by Type of Manufacturer 5.1. Introduction 5.2. Active Pharmaceutical Ingredient Market Size and Growth Rate by Type of Manufacturer (2021-2030) 5.3. Captive APIs 5.3.1. Captive APIs Market Size and Growth Rate (2021-2030) 5.7. Merchant APIs 5.7.1. Merchant APIs Market Size and Growth Rate (2021-2030) 5.5. Generic APIs 5.5.1. Generic APIs Market Size and Growth Rate (2021-2030) 5.6. Innovative APIs 5.6.1. Innovative APIs Market Size and Growth Rate (2019- 2030) 6. Active Pharmaceutical Ingredient Market by Type 6.1. Introduction 6.2. Active Pharmaceutical Ingredient Market Size and Growth Rate by Type (2021-2030) 6.3. Generic APIs 6.3.1. Generic APIs Market Size and Growth Rate (2021-2030) 6.7. Innovative APIs 6.7.1. Innovative APIs Market Size and Growth Rate (2021-2030) 7. Active Pharmaceutical Ingredient Market by Application 7.1. Introduction 7.2. Active Pharmaceutical Ingredient Market Size and Growth Rate by Application (2021-2030) 7.3. Cardiovascular Diseases 7.3.1. Cardiovascular Diseases Market Size and Growth Rate (2019- 2030) 7.7. Oncology 7.7.1. Oncology Market Size and Growth Rate (2019- 2030) 7.5. CNS & Neurological Disorders 7.5.1. CNS & Neurological Disorders Market Size and Growth Rate (2021-2030) 7.6. Orthopedic Disorders 7.6.1. Orthopedic Disorders Market Size and Growth Rate (2021-2030) 7.7. Endocrinology 7.7.1. Endocrinology Market Size and Growth Rate (2021-2030) 7.3. Pulmonology 7.3.1. Pulmonology Market Size and Growth Rate (2019- 2030) 7.7. Gastrointestinal Disorders 7.7.1. Gastrointestinal Disorders Market Size and Growth Rate (2019- 2030) 7.5. Nephrology 7.5.1. Nephrology Market Size and Growth Rate (2021-2030) 7.6. Ophthalmology 7.6.1. Ophthalmology Market Size and Growth Rate (2021-2030) 7.7. Others 7.7.1. Others Market Size and Growth Rate (2021-2030)
10. Company Profiles 10.1. Albemarle Corporation 10.1.1. Business Overview 10.1.2. Service Portfolio 10.1.3. Strategic Developments 10.1.7. Financial Overview
10.2. AurobindoPharma 10.2.1. Business Overview 10.2.2. Service Portfolio 10.2.3. Strategic Developments 10.2.7. Financial Overview
10.3. Reddy’s Laboratories Ltd. 10.3.1. Business Overview 10.3.2. Service Portfolio 10.3.3. Strategic Developments 10.3.7. Financial Overview
10.7. AbbVieInc 10.7.1. Business Overview 10.7.2. Service Portfolio 10.7.3. Strategic Developments 10.7.7. Financial Overview
10.5. Teva Pharmaceutical Industries Ltd 10.5.1. Business Overview 10.5.2. Service Portfolio 10.5.3. Strategic Developments 10.5.7. Financial Overview
10.6. Mylan N.V. 10.6.1. Business Overview 10.6.2. Service Portfolio 10.6.3. Strategic Developments 10.6.7. Financial Overview
10.7. CiplaInc 10.7.1. Business Overview 10.7.2. Service Portfolio 10.7.3. Strategic Developments 10.7.7. Financial Overview
10.8. BoehringerIngelheim International GmbH 10.8.1. Business Overview 10.8.2. Service Portfolio 10.8.3. Strategic Developments 10.8.7. Financial Overview
10.9. Merck & Co., Inc 10.9.1. Business Overview 10.9.2. Service Portfolio 10.9.3. Strategic Developments 10.9.7. Financial Overview
10.10. Sun Pharmaceutical Industries Ltd 10.10.1. Business Overview 10.10.2. Service Portfolio 10.10.3. Strategic Developments 10.10.7. Financial Overview
10.11. Bristol-Myers Squibb Company 10.11.1. Business Overview 10.11.2. Service Portfolio 10.11.3. Strategic Developments 10.11.7. Financial Overview
11. List of Tables and Figures Table Active Pharmaceutical Ingredient Market Size and Market Share by Type of Synthesis(2021-2023) Table Active Pharmaceutical Ingredient Market Size and Market Share by Type of Synthesis(2023-2030) Figure Biotech Market Size and Growth Rate (2021-2030) Figure Monoclonal Antibodies Market Size and Growth Rate (2021-2030) Figure Recombinant Proteins Market Size and Growth Rate (2021-2030) Figure Vaccines Market Size and Growth Rate (2021-2030) Figure Synthetic Market Size and Growth Rate (2021-2030)
Table Active Pharmaceutical Ingredient Market Size and Market Share by Type of Manufacturer (2021-2023) Table Active Pharmaceutical Ingredient Market Size and Market Share by Type of Manufacturer (2023-2030) Figure Captive APIs Market Size and Growth Rate (2021-2030) Figure Merchant APIs Market Size and Growth Rate (2021-2030) Figure Generic APIs Market Size and Growth Rate (2021-2030) Figure Innovative APIs Market Size and Growth Rate (2021-2030)
Table Active Pharmaceutical Ingredient Market Size and Market Share by Type (2021-2023) Table Active Pharmaceutical Ingredient Market Size and Market Share by Type (2023-2030) Figure Generic APIs Market Size and Growth Rate (2021-2030) Figure Innovative APIs Market Size and Growth Rate (2021-2030) Figure Specialty Clinics Market Size and Growth Rate (2021-2030) Table Active Pharmaceutical Ingredient Market Size and Market Share by Application (2021-2023) Table Active Pharmaceutical Ingredient Market Size and Market Share by Application(2023-2030) Figure Cardiovascular Diseases Market Size and Growth Rate (2021-2030) Figure Oncology Market Size and Growth Rate (2021-2030) Figure CNS & Neurological Disorders Market Size and Growth Rate (2021-2030) Figure Orthopedic Disorders Market Size and Growth Rate (2021-2030) Figure Endocrinology Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Figure Pulmonology Market Size and Growth Rate (2021-2030) Figure Gastrointestinal Disorders Market Size and Growth Rate (2021-2030) Figure Nephrology Market Size and Growth Rate (2021-2030) Figure Ophthalmology Market Size and Growth Rate (2021-2030) Figure Others Market Size and Growth Rate (2021-2030)
Table Active Pharmaceutical Ingredient Market by Regions (2021-2023) Table Active Pharmaceutical Ingredient Market by Regions (2023-2030) Figure North America Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table North America Active Pharmaceutical Ingredient Market by Type (2021-2023) Table North America Active Pharmaceutical Ingredient Market by Type (2023-2030) Table North America Active Pharmaceutical Ingredient Market by Application (2021-2023) Table North America Active Pharmaceutical Ingredient Market by Application (2023-2030) Table North America Active Pharmaceutical Ingredient Market by Country (2021-2023) Table North America Active Pharmaceutical Ingredient Market by Country (2023-2030) Figure United States Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table United States Active Pharmaceutical Ingredient Market by Type (2021-2023) Table United States Active Pharmaceutical Ingredient Market by Type (2023-2030) Table United States Active Pharmaceutical Ingredient Market by Application (2021-2023) Table United States Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Canada Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Canada Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Canada Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Canada Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Canada Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Europe Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Europe Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Europe Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Europe Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Europe Active Pharmaceutical Ingredient Market by Application (2023-2030) Table Europe Active Pharmaceutical Ingredient Market by Country (2021-2023) Table Europe Active Pharmaceutical Ingredient Market by Country (2023-2030) Figure Germany Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Germany Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Germany Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Germany Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Germany Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure France Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table France Active Pharmaceutical Ingredient Market by Type (2021-2023) Table France Active Pharmaceutical Ingredient Market by Type (2023-2030) Table France Active Pharmaceutical Ingredient Market by Application (2021-2023) Table France Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure UK Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table UK Active Pharmaceutical Ingredient Market by Type (2021-2023) Table UK Active Pharmaceutical Ingredient Market by Type (2023-2030) Table UK Active Pharmaceutical Ingredient Market by Application (2021-2023) Table UK Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Russia Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Russia Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Russia Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Russia Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Russia Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Italy Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Italy Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Italy Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Italy Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Italy Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Rest of Europe Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Rest of Europe Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Rest of Europe Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Rest of Europe Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Rest of Europe Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Asia-Pacific Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Asia-Pacific Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Asia-Pacific Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Asia-Pacific Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Asia-Pacific Active Pharmaceutical Ingredient Market by Application (2023-2030) Table Asia-Pacific Active Pharmaceutical Ingredient Market by Country (2021-2023) Table Asia-Pacific Active Pharmaceutical Ingredient Market by Country (2023-2030) Figure China Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table China Active Pharmaceutical Ingredient Market by Type (2021-2023) Table China Active Pharmaceutical Ingredient Market by Type (2023-2030) Table China Active Pharmaceutical Ingredient Market by Application (2021-2023) Table China Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Japan Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Japan Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Japan Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Japan Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Japan Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Korea Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Korea Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Korea Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Korea Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Korea Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure India Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table India Active Pharmaceutical Ingredient Market by Type (2021-2023) Table India Active Pharmaceutical Ingredient Market by Type (2023-2030) Table India Active Pharmaceutical Ingredient Market by Application (2021-2023) Table India Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Southeast Asia Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Southeast Asia Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Southeast Asia Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Southeast Asia Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Southeast Asia Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Rest of Asia-Pacific Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Rest of Asia-Pacific Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Rest of Asia-Pacific Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Rest of Asia-Pacific Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Rest of Asia-Pacific Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure South America Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table South America Active Pharmaceutical Ingredient Market by Type (2021-2023) Table South America Active Pharmaceutical Ingredient Market by Type (2023-2030) Table South America Active Pharmaceutical Ingredient Market by Application (2021-2023) Table South America Active Pharmaceutical Ingredient Market by Application (2023-2030) Table South America Active Pharmaceutical Ingredient Market by Country (2021-2023) Table South America Active Pharmaceutical Ingredient Market by Country (2023-2030) Figure Brazil Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Brazil Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Brazil Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Brazil Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Brazil Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Mexico Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Mexico Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Mexico Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Mexico Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Mexico Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Columbia Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Columbia Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Columbia Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Columbia Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Columbia Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Rest of South America Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Rest of South America Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Rest of South America Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Rest of South America Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Rest of South America Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Middle East and Africa Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Middle East and Africa Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Middle East and Africa Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Middle East and Africa Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Middle East and Africa Active Pharmaceutical Ingredient Market by Country (2021-2023) Table Middle East and Africa Active Pharmaceutical Ingredient Market by Country (2023-2030) Figure Saudi Arabia Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Saudi Arabia Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Saudi Arabia Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Saudi Arabia Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Saudi Arabia Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure United Arab Emirates Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table United Arab Emirates Active Pharmaceutical Ingredient Market by Type (2021-2023) Table United Arab Emirates Active Pharmaceutical Ingredient Market by Type (2023-2030) Table United Arab Emirates Active Pharmaceutical Ingredient Market by Application (2021-2023) Table United Arab Emirates Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure South Africa Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table South Africa Active Pharmaceutical Ingredient Market by Type (2021-2023) Table South Africa Active Pharmaceutical Ingredient Market by Type (2023-2030) Table South Africa Active Pharmaceutical Ingredient Market by Application (2021-2023) Table South Africa Active Pharmaceutical Ingredient Market by Application (2023-2030) Figure Rest of Middle East and Africa Active Pharmaceutical Ingredient Market Size and Growth Rate (2021-2030) Table Rest of Middle East and Africa Active Pharmaceutical Ingredient Market by Type (2021-2023) Table Rest of Middle East and Africa Active Pharmaceutical Ingredient Market by Type (2023-2030) Table Rest of Middle East and Africa Active Pharmaceutical Ingredient Market by Application (2021-2023) Table Rest of Middle East and Africa Active Pharmaceutical Ingredient Market by Application (2023-2030)
Table Olympus Corporation Active Pharmaceutical Ingredient Market Financial Overview Table Medtronic Active Pharmaceutical Ingredient Market Financial Overview Table Fujifilm Holdings Corporation Active Pharmaceutical Ingredient Market Financial Overview Table Boston Scientific Corporation Active Pharmaceutical Ingredient Market Financial Overview Table Johnson & Johnson (Ethicon) Active Pharmaceutical Ingredient Market Financial Overview Table Karl Storz Active Pharmaceutical Ingredient Market Financial Overview Table PENTAX Medical (Hoya Corporation) Active Pharmaceutical Ingredient Market Financial Overview Table Cook Medical Active Pharmaceutical Ingredient Market Financial Overview Table CONMED Corporation Active Pharmaceutical Ingredient Market Financial Overview Table Stryker Corporation Active Pharmaceutical Ingredient Market Financial Overview Table Apollo Endosurgery, Inc. (US) Active Pharmaceutical Ingredient Market Financial Overview Table Endo Tools Therapeutics S.A. (Belgium) Active Pharmaceutical Ingredient Market Financial Overview
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Biologics Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Global Biologics Market for the past year and forecasts for the next six years. Global Biologics Market. Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Biologics Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Biologics Market from different application industries in different regions.
Market Segmentation By Type of Synthesis Biotech Monoclonal Antibodies Recombinant Proteins Vaccines Synthetic
By Type of Manufacturer Captive APIs Merchant APIs Generic APIs Innovative APIs
By Geography North America U.S. Canada Europe Germany France United Kingdom Rest of Europe Asia Pacific China Japan India Southeast Asia Rest of Asia Pacific Latin America Brazil Rest of Latin America Middle East & Africa (MEA) GCC North Africa South Africa Rest of Middle East & Africa
